ATEA PHARMACEUTICALS, INC.

Insiders Atea Pharmaceuticals, Inc.

Equities

AVIR

US04683R1068

Market Closed - Nasdaq Other stock markets 01:30:00 10/05/2024 am IST			5-day change	1st Jan Change
3.93 ^USD	0.00%		+2.61%	+28.85%

27/03	Atea Pharmaceuticals, Inc. Completes Patient Enrollment in Global Phase 3 Sunrise-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients	CI
28/02	Atea Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Atea Pharmaceuticals, Inc. Announces Executive Changes	10/22/10	CI
Atea Pharmaceuticals, Inc. Appoints Claudio Avila as Senior Vice President of Medical Affairs	15/21/15	CI
Atea Pharmaceuticals Appoints Jerome Adams to Board of Directors	20/21/20	CI
Atea Pharmaceuticals, Inc. Announces Resignation of Isaac Cheng as Class III Director	19/21/19	CI
Atea Pharmaceuticals Expands Senior Management Team with Key Additions in Regulatory Affairs and Investor Relations and Corporate Communications	19/21/19	CI
Atea Pharmaceuticals, Inc. Appoints Barbara Duncan to the Board of Directors	06/20/06	CI
Atea Pharmaceuticals, Inc. Appoints Polly Murphy, D.V.M, Ph.D., to the Board of Directors	14/20/14	CI
Atea Pharmaceuticals, Inc. Announces Executive Appointments	24/20/24	CI
Atea Pharmaceuticals, Inc. Appoints Janet Hammond as Chief Development Officer	10/20/10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW